Related Experiment Video

Updated: Mar 1, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?

Udaya S Tantry1, Eliano P Navarese2, Paul A Gurbel1

  • 1Cardiac Catheterization Laboratory, Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA.

Interventional Cardiology Clinics
|June 6, 2017
PubMed

Insights

Gender differences in blood clot formation (thrombogenicity) are reviewed. Women may have increased ischemic events in acute coronary syndromes, warranting further research into sex-based variations in platelet function.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Reproductive Endocrinology

Background:

  • Ischemic complications in acute coronary syndrome (ACS) stem from thrombus formation, where platelet activation is key.
  • Dual antiplatelet therapy strategies in ACS trials show women experience more ischemic events.
  • The role of estrogen in premenopausal women's cardiovascular protection remains debated.

Purpose of the Study:

  • To review and discuss intrinsic gender differences in thrombogenicity.
  • To explore the potential influence of estrogen on platelet function and gender-based thrombotic risk.

Main Methods:

  • Literature review of studies investigating gender-based thrombogenicity.
  • Analysis of clinical trial data comparing ischemic event rates between genders.
  • Examination of in vitro studies on estrogen's effect on platelet function.

Main Results:

  • Women appear to have higher rates of ischemic events in ACS, particularly with dual antiplatelet therapy.
  • In vitro evidence suggests estrogen can attenuate platelet function.
  • Data indicate potential intrinsic gender differences in thrombogenicity.

Conclusions:

  • Significant gender differences in thrombogenicity exist and merit further investigation.
  • Understanding these sex-based variations is crucial for optimizing ACS treatment and prevention strategies.
  • Estrogen's role in modulating platelet activity warrants deeper exploration in the context of cardiovascular risk.

Keywords:
Antiplatelet therapyGender differencePlatelet functionThrombogenicity

More Related Videos

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

1.3K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316